NZ603997A - Chemically Modified Factor IX - Google Patents

Chemically Modified Factor IX

Info

Publication number
NZ603997A
NZ603997A NZ603997A NZ60399708A NZ603997A NZ 603997 A NZ603997 A NZ 603997A NZ 603997 A NZ603997 A NZ 603997A NZ 60399708 A NZ60399708 A NZ 60399708A NZ 603997 A NZ603997 A NZ 603997A
Authority
NZ
New Zealand
Prior art keywords
fix
region
hydrophilic polymer
soluble hydrophilic
covalently coupled
Prior art date
Application number
NZ603997A
Other languages
English (en)
Inventor
Peter Turecek
Friedrich Scheifflinger
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of NZ603997A publication Critical patent/NZ603997A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ603997A 2007-12-27 2008-12-19 Chemically Modified Factor IX NZ603997A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US926307P 2007-12-27 2007-12-27

Publications (1)

Publication Number Publication Date
NZ603997A true NZ603997A (en) 2013-02-22

Family

ID=40344940

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ603997A NZ603997A (en) 2007-12-27 2008-12-19 Chemically Modified Factor IX
NZ598193A NZ598193A (en) 2007-12-27 2008-12-19 Chemically Modified Factor IX
NZ585835A NZ585835A (en) 2007-12-27 2008-12-19 Chemically modified factor IX comprising a hydrophilic polymer attached via a releasable linker

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ598193A NZ598193A (en) 2007-12-27 2008-12-19 Chemically Modified Factor IX
NZ585835A NZ585835A (en) 2007-12-27 2008-12-19 Chemically modified factor IX comprising a hydrophilic polymer attached via a releasable linker

Country Status (11)

Country Link
US (2) US20090176708A1 (enExample)
EP (4) EP2568043A1 (enExample)
JP (1) JP2011507919A (enExample)
KR (1) KR20100110799A (enExample)
CN (1) CN101952422A (enExample)
AU (1) AU2008342260B2 (enExample)
CA (1) CA2709960A1 (enExample)
IL (1) IL206095A0 (enExample)
NZ (3) NZ603997A (enExample)
RU (1) RU2010131189A (enExample)
WO (1) WO2009083187A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2353588B1 (en) 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
US10772942B2 (en) 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
US20220378840A1 (en) * 2019-11-29 2022-12-01 Rutgers, The State University Of New Jersey Compositions, kits and methods for storage of blood products and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS538750B2 (enExample) 1971-08-18 1978-03-31
AT348548B (de) 1977-04-08 1979-02-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung von alsblutplasma- expander geeignerter hydroxyaethylstaerke
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
DE3313600A1 (de) * 1983-04-14 1984-10-18 Laevosan-Gesellschaft mbH & Co. KG, Linz Plasmastreckmittel auf staerkebasis und verfahren zu ihrer herstellung
DE19975071I2 (de) 1989-06-16 2000-02-03 Fresenius Ag Hydroxyethylstaerke als Plasmaexpander Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
DE4310974C2 (de) * 1993-04-03 1996-08-01 Fresenius Ag Verwendung von Hydroxyethylstärke zur Verbesserung der Mikrozirkulation
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
EP0973544B1 (de) * 1997-04-08 2001-06-27 Baxter Aktiengesellschaft Immuntolerante prothrombinkomplex-präparation
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1694315A4 (en) * 2003-12-03 2009-10-28 Novo Nordisk As FACTOR IX GLYCOPEGYL
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101215226B1 (ko) 2004-03-01 2012-12-26 베. 브라운 멜중엔 악티엔게젤샤프트 하이드록시에틸전분
WO2005092928A1 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
WO2006018204A1 (en) * 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
JP2008532966A (ja) * 2005-03-11 2008-08-21 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不活性出発物質からの生理活性糖タンパク質の生成
WO2007101681A1 (en) 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
CN101454267B (zh) 2006-03-29 2012-09-26 帝斯曼知识产权资产管理有限公司 姜黄素的合成
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
EP2155865B1 (en) * 2007-06-15 2014-09-17 National Research Council Of Canada Engineered versions of polysialyltransferases with enhanced enzymatic properties

Also Published As

Publication number Publication date
AU2008342260A1 (en) 2009-07-09
EP2247723A1 (en) 2010-11-10
CN101952422A (zh) 2011-01-19
US20090176708A1 (en) 2009-07-09
NZ598193A (en) 2012-12-21
CA2709960A1 (en) 2009-07-09
JP2011507919A (ja) 2011-03-10
US20120177625A1 (en) 2012-07-12
AU2008342260B2 (en) 2013-10-17
NZ585835A (en) 2012-07-27
EP2568043A1 (en) 2013-03-13
EP2568042A1 (en) 2013-03-13
IL206095A0 (en) 2010-11-30
KR20100110799A (ko) 2010-10-13
EP2568041A1 (en) 2013-03-13
RU2010131189A (ru) 2012-02-10
WO2009083187A8 (en) 2009-09-17
WO2009083187A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
EP1403304A1 (en) Crosslinked elastin and process for producing the same
NZ603997A (en) Chemically Modified Factor IX
WO2008058963A8 (fr) Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
CN105039465B (zh) 一种酶催化二硫键交联的天然高分子水凝胶及其制备方法
DE60138641D1 (de) Herstellung von mikrokügelchen
WO2009007531A3 (fr) Support collagenique modifie par greffage covalent de molecules d'adhesion
BRPI0410185A (pt) composição para manter a viabilidade de um orgão e célula
WO2002054946A3 (en) Ultrasonic imaging of perfusion using gases with different partial pressures
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
WO2010011096A3 (en) A polypeptide complex comprising non-peptidyl polymer having three functional ends
Zhao et al. Engineered bicomponent adhesives with instantaneous and superior adhesion performance for wound sealing and healing applications
ATE420116T1 (de) Verfahren zur herstellung von cellulosesulfat mit verbesserten eigenschaften
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
EP2628749A3 (en) Antimicrobial kinocidin compostions and methods of use
WO2007062610A3 (es) Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos
DE60138804D1 (de) Verfahren zur herstellung von physiologisch aktiven substanzen enthaltenden dispersionen unter anwendung von hochdruck und hochscherkraft
EP2626087B1 (en) Tissue adhesive film and method for producing same
NZ582669A (en) Hydrolysable polymeric FMOC-linker
WO2007109155A3 (en) Assays for detection of antibodies to lysosomal enzymes
CN109266639A (zh) 一种双重固定化酶及其制备方法和应用
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
Folikumah et al. Thiol–thioester exchange reactions in precursors enable pH-triggered hydrogel formation
WO2006063758A3 (en) Process for the preparation of two and three dimensional polymer scaffolds
ATE442434T1 (de) Verfahren zur unterdrückung einer immunsystemreaktion gegen gewebe- oder zelltransplantate
CN102432865A (zh) 聚乙二醇修饰的氧化石墨烯及其应用

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 DEC 2015 BY CULLENS

Effective date: 20130826

LAPS Patent lapsed